BeiGene RMB22.2 billion Shanghai IPO
The offering, equivalent to $3.5 billion, is the largest biotech IPO to date in 2021
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Yonghe HK$1.49 billion IPO
The shares are listed on the HKEX
CANbridge Pharmaceuticals HK$685 million IPO
We advised CANbridge Pharmaceuticals on its IPO and HKEX listing
Merck $8 billion notes offering, including its debut sustainability debt
The offering includes five tranches of notes
Olympus $500 million senior notes offering
The debut offering consisted of 2.143% senior notes due 2026
Privia Health $174 million secondary offering
We advised Privia on its SEC-registered offering of stock
Alignment Healthcare $193 million SEC-registered secondary offering
The shares are listed on the Nasdaq Global Select Market
Apria $141.7 million secondary offering
The shares are listed on the Nasdaq Global Select Market
Revolution Medicines $250 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Affimed $100 million at-the-market offering
The shares are listed on the Nasdaq Global Market